Latest news with #diagnostic
Yahoo
6 days ago
- Business
- Yahoo
Stroke Diagnostic and Therapeutic Market to Hit Valuation of US$ 81.68 Billion By 2033
The stroke market is experiencing unprecedented growth, fueled by intense corporate investment and disruptive technologies like AI. This surge is rapidly advancing diagnostic speed and therapeutic options, fundamentally transforming the entire continuum of patient care. Chicago, July 17, 2025 (GLOBE NEWSWIRE) -- The global stroke diagnostic and therapeutic market was valued at US$ 42.07 billion in 2024 and is expected to reach US$ 81.68 billion by 2033, growing at a CAGR of 7.65% during the forecast period 2025–2033. Within the stroke diagnostic and therapeutic market, the segment for endovascular therapy (EVT) is experiencing unprecedented growth, solidified by a wave of compelling clinical evidence. A significant recent development involves a standardized, image-guided neurosurgical technique for clot removal in intracerebral hemorrhage, which has been shown to substantially improve patient outcomes; remarkably, the number needed to treat to achieve functional independence with this method is just eight patients. For ischemic stroke patients with large vessel occlusion and an extensive ischemic core, the benefits of EVT are now undisputed, with five randomized controlled trials confirming less disability compared to medical management alone. Request Sample Copy: The positive data is quantifiable, showing that for every 100 patients treated with EVT, an additional 17 achieve a better functional outcome and six more lives are saved. Further refining the treatment protocol, a post hoc analysis has revealed that administering intravenous thrombolysis (IVT) less than 140 minutes before EVT significantly boosts positive results. This efficacy extends to more distal blockages, as highlighted by a French registry on distal M2 MCA occlusions which reported successful reperfusion in 85% of patients undergoing EVT. The therapeutic landscape is also shifting, as five phase 3 trials have now established the noninferiority of tenecteplase when compared directly to alteplase, a change poised to significantly impact the stroke diagnostic and therapeutic market. Key Findings in Stroke Diagnostics and Therapeutics Market Market Forecast (2033) US$ 81.68 billion CAGR 7.65% Largest Region (2024) North America (29%) By Type Diagnostics (56.31%) By Application Ischemic Stroke (62.27%) Top Drivers Increasing global prevalence of stroke and associated risk factors Technological advancements in diagnostic imaging and minimally invasive therapies Rising healthcare expenditure and awareness of early stroke diagnosis Top Trends Growing adoption of artificial intelligence in stroke diagnosis Shift towards minimally invasive endovascular treatment procedures Expansion of telemedicine and remote tele-stroke services Top Challenges Stringent regulatory approvals for new devices and therapeutics Pharmaceutical Pipeline for Ischemic Stroke Explodes with Over 200 Novel Drugs The pharmaceutical pipeline is a highly competitive and lucrative corner of the stroke diagnostic and therapeutic market. The sheer scale of this research and development effort is immense, with over 50 companies actively working on more than 55 distinct pipeline drugs. In total, the current ischemic stroke pipeline features an impressive 202 drugs in various stages of development from 182 different companies and institutions, a testament to the vibrancy of the stroke diagnostic and therapeutic market. The preclinical stage is currently the most active area of innovation, with 76 unique drugs being investigated, signaling a robust future for novel therapies. Several candidates are progressing through the clinical trial process, generating significant market anticipation. Among them, JX10, a promising drug with both thrombolytic and anti-inflammatory properties, is currently in Phase II trials, while the neuroprotective agent Nelonemdaz has advanced to the critical Phase III stage. Adding to the momentum, an investigational drug known as AB126 is scheduled to commence a Phase I/II clinical trial in the first half of 2024. This wave of innovation is already impacting clinical practice, as highlighted by NICE's official recommendation in July 2024 to use tenecteplase for acute ischaemic stroke in adults. New Surgical and Drug Therapies Redefine Hemorrhagic Stroke Intervention Strategies Progress in managing hemorrhagic stroke is accelerating, creating new opportunities within the stroke diagnostic and therapeutic market. A landmark 2024 study has demonstrated for the first time the benefit of a standardized, image-guided microsurgical technique for clot removal over medical management alone, specifically leading to better six-month outcomes for patients with lobar hemorrhage. On the pharmaceutical front, for patients experiencing major intracranial bleeding related to Factor Xa inhibitors, the reversal agent andexanet alfa achieved hemostasis in a significant 67% of patients in a key trial. Another major advancement is seen in the treatment of subacute and chronic subdural hematoma, where middle meningeal artery embolization used as an adjunct to surgery drastically reduces the likelihood of recurrence. The recurrence rate within 90 days plummeted to just 4.1% in the group receiving embolization with surgery, compared to 11.3% in the surgery-only group. Alongside these interventions, research confirms that intensive blood pressure reduction in the initial stages of intracerebral hemorrhage effectively lessens the absolute growth of hematomas. Despite these gains, the precise role of surgery in hemorrhagic stroke continues to be a subject of intense research, shaping the future of the stroke diagnostic and therapeutic market. Telestroke Networks Emerge as a Critical Solution to Access-to-Care Gaps Telemedicine is proving to be an indispensable tool, expanding the reach of the stroke diagnostic and therapeutic market to underserved populations. The integration of telestroke platforms facilitates immediate remote consultations and allows for the continuous monitoring of patients, which is particularly crucial for improving care access in regions with limited specialized healthcare resources. The need for such systems is underscored by persistent gaps in public awareness; one survey revealed that only 38% of people could identify all major stroke symptoms and knew to call emergency services. This knowledge deficit contributes to treatment delays, as patients who arrive at an emergency room within three hours of their first symptoms often experience significantly less disability three months later. A nationwide study in the US highlighted the scale of this problem, finding that 54% of stroke patients arrived at a hospital more than two hours after their symptoms began, with these critical delays being more common among older, female, and Black patients. Telestroke networks directly address this challenge by providing a vital bridge, enabling rapid remote evaluation by neurologists to expedite life-saving treatment decisions. Technology-Infused Rehabilitation Creates New Pathways for Long-Term Stroke Recovery The field of stroke rehabilitation is being reinvented, representing a rapidly evolving segment of the stroke diagnostic and therapeutic market. Robotic devices are becoming central to this new paradigm, delivering the kind of highly targeted and intensive therapy needed to help patients regain critical motor function. A significant market development is the Vivistim Paired VNS System, a surgically implanted device that recently gained FDA approval for chronic stroke patients. This innovative vagus nerve stimulation system is specifically designed for individuals with moderate to severe upper arm impairment six months to over 20 years after their stroke. While the surgical procedure to implant the device has been established for decades, its application for stroke recovery is a novel and promising approach. Following implantation, patients engage in a rigorous six-week intensive rehabilitation program. This is complemented by the growing use of wearable technology, such as inertial measurement units and electromyography sensors, which allow for highly tailored assessments and therapies. Concurrently, home-based rehabilitation programs are gaining significant traction, offering patients a more convenient and cost-effective path to recovery. Advanced Neuroimaging Technologies Provide Unprecedented Clarity in Stroke Diagnosis The diagnostic imaging sector of the stroke diagnostic and therapeutic market is advancing rapidly, with new technologies providing unparalleled insights into the brain to facilitate earlier and more precise diagnoses. High-resolution magnetic resonance imaging (MRI) and computed tomography (CT) scans remain the cornerstones for the early detection and exact localization of stroke lesions. While non-contrast CT is still a primary modality for the initial evaluation of a suspected stroke, recent advances have boosted its overall diagnostic sensitivity to 64% and its specificity to 85%. A major technological leap occurred in December 2023 with the unveiling of the NAEOTOM Alpha, a pioneering diagnostic imaging system poised to set new standards in the field. Simultaneously, automated stroke detection software from leading companies like Brainomix, RapidAI, and is achieving widespread adoption and gaining significant market traction. The integration of artificial intelligence with this imaging data is a game-changer; it can now help clinicians predict the final infarct volume and accurately assess the risk of hemorrhagic transformation. Operator and Hospital Experience Emerge as Key Drivers of Patient Outcomes The correlation between procedural volume and patient outcomes is becoming a critical point of analysis for stakeholders in the stroke diagnostic and therapeutic market. A comprehensive study involving over 3,000 patients revealed a clear benefit associated with experienced clinicians; it found that higher proceduralist volume, defined as performing 18 or more endovascular therapies per year, was directly associated with reduced in-hospital mortality. The data showed that the absolute risk of death was 4.8% lower in this high-volume group. Another study, however, observed a paradoxical relationship where higher-volume hospitals had worse outcomes, a finding likely attributable to these centers treating a greater proportion of severe and complex cases. This was supported by an analysis where the odds of in-hospital mortality actually increased in higher-volume quartiles. A snapshot from Florida in 2019 showed that of the 297 hospitals, 105 performed mechanical thrombectomy. Among these, 54 were classified as high-volume centers (≥15 MTs/year), with a median of 59.5 cases, compared to a median of just two cases at low-volume hospitals. Stroke's Staggering Global Impact Drives Demand for Innovative Care Solutions Stroke persists as a formidable global health crisis, which in turn fuels the immense global stroke diagnostic and therapeutic market. In 2021 alone, there were 93.8 million stroke survivors and 11.9 million new cases, highlighting the immense scale of the issue. The global cost of stroke is now estimated to be over US$890 billion, placing an enormous economic burden on healthcare systems. Ischemic stroke was the predominant type, accounting for 65.3% of all new strokes in 2021, with a slightly higher incidence among males (52.6%). There are significant regional disparities in both incidence and mortality, revealing inequities in access to care. The lowest age-standardized stroke incidence was observed in Luxembourg (57.7 per 100,000), while the Solomon Islands faced the highest rate (355.0 per 100,000). Similarly, Singapore reported the lowest stroke death rate at 14.2 per 100,000, which stands in stark contrast to North Macedonia, the country with the highest mortality rate at 277.4 per 100,000, illustrating the urgent need for globally accessible and effective solutions from the stroke diagnostic and therapeutic market. Tailor This Report to Your Specific Business Needs: Expanding Therapeutic Windows for Intervention Offer Hope for More Patients Recent clinical research is fundamentally challenging and expanding the traditionally accepted timeframes for effective stroke intervention, a development with profound implications for the stroke diagnostic and therapeutic market. The CT for Late Endovascular Reperfusion (CLEAR) study, which enrolled 2,451 patients, was designed specifically to assess the benefits of EVT within an extended time window, suggesting that even patients with a large ischemic core may still benefit. This is reinforced by a propensity score-matched analysis which found that approximately one-third of large vessel occlusion patients with persistent deficits beyond the 16-hour mark still met the stringent criteria for late-window trials like DAWN or DEFUSE 3. When EVT was performed in these late-presenting patients, it resulted in 11.08-fold higher odds of achieving a good functional outcome. These findings add urgency to the treatment process, as demonstrated by foundational studies like MR CLEAN, which showed that every single hour of delay in achieving reperfusion led to a 7.7% decreased probability of the patient regaining functional independence. Likewise, the REVASCAT trial quantified the cost of delay, showing a 26% decrease in the likelihood of a favorable outcome for every 30-minute delay in reperfusion. Top Companies in Stroke Diagnostic and Therapeutic Market Abbott Laboratories Boston Scientific Corporation Cerebrotech Medical Systems, Inc. Cordis Corporation GE Healthcare Genentech Inc. Gowerlabs Hyperfine MRI Koninklijke Philips N.V. Medfield Diagnostics Medtronic plc. Merck & Co., Inc. Neural Analytics NIRX Samsung Neurologica Siemens AG Stryker Corporation Other Prominent Players Market Segmentation Overview By Type Diagnostics Magnetic Resonance Imaging (MRI) Computed Tomography Scan (CT scan) Electrocardiography Carotid Ultrasound Cerebral Angiography Others Therapeutics Tissue Plasminogen Activator Antiplatelet Antihypertensive Anticoagulant By Application Hemorrhagic Stroke Ischemic Stroke By Region North America Europe Asia Pacific Middle East Africa South America Want Deeper Insights? Book a Free Call with an Expert: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNA
14-07-2025
- Business
- CNA
OraSure Technologies received takeover bid from industry entrepreneur, sources say
NEW YORK :Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others - people the sources did not identify - Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27 per cent in the last 12 months and is off 77 per cent over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher, Siemens, Roche and Thermo Fisher Scientific capturing the biggest market share.
Reuters
14-07-2025
- Business
- Reuters
OraSure Technologies received takeover bid from industry entrepreneur, sources say
NEW YORK, July 14 (Reuters) - Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies (OSUR.O), opens new tab with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others -- people the sources did not identify -- Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories (ABT.N), opens new tab in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27% in the last 12 months and is off 77% over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher (DHR.N), opens new tab, Siemens ( opens new tab, Roche (ROG.S), opens new tab and Thermo Fisher Scientific (TMO.N), opens new tab capturing the biggest market share.
Yahoo
14-07-2025
- Business
- Yahoo
OraSure Technologies received takeover bid from industry entrepreneur, sources say
By Svea Herbst-Bayliss NEW YORK (Reuters) -Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. In June, Zwanziger submitted an unsolicited all-cash proposal to buy the Bethlehem, Pennsylvania-headquartered company, known for its COVID-19 rapid antigen tests, the sources said. Along with a prominent Wall Street investor and others -- people the sources did not identify -- Zwanziger proposed paying between $3.50 and $4.00 a share for OraSure. OraSure's stock was trading aT $3.18 on Monday morning, leaving it with a market capitalization of $238.6 million. The company's board rejected the offer not long after it was sent, without any discussions between the parties, the three sources said. A company representative did not immediately respond to a request for comment. A representative for Zwanziger, a serial deal maker who cemented his reputation through at-home blood glucose testing, could not be reached for comment. Zwanziger has built and sold a handful of diagnostic companies during his long career, and sold diagnostic test manufacturer Alere Abbott Laboratories in 2017 for around $5.3 billion. The rebuffed offer for OraSure was his second effort to combine with the company, according to one of the sources. In 2022, only a few months after the company named Carrie Eglinton Manner as its chief executive officer, Zwanziger proposed a merger through a stock swap, but terms could not be reached, the source said. OraSure appealed to Zwanziger because of its solid core technology and he thought he could turn around the company's fortunes quickly with a new team, the sources said. The company's stock price has fallen 27% in the last 12 months and is off 77% over the last five years. Quarterly revenue has been dropping since early 2023 as COVID-19 era sales dried up. OraSure has been attempting to diversify its business as a result, buying Sherlock Biosciences late last year for its molecular diagnostics platform. Point of care diagnostic companies offer accurate results in real time to measure cholesterol, and detect flu and pregnancy, for example. But the industry still remains highly fragmented with companies such as Danaher, Siemens, Roche and Thermo Fisher Scientific capturing the biggest market share. Sign in to access your portfolio
CTV News
30-06-2025
- Health
- CTV News
Vancouver now home to fastest PET/CT scanner in Canada
BC Cancer has rolled out a new diagnostic tool that it says is the fastest and most advanced of its kind in Canada. A new cancer screening machine that recently began operating at the BC Cancer Centre in Vancouver is the fastest and most advanced in Canada, according to officials. The Quadra PET/CT scanner is the first of its kind in the country, and it can capture a much larger picture than previous generations and is about 22 times more sensitive. 'It is the equivalent of four PET scanners put together, and essentially the area covers from the head to the pelvis,' said Dr. François Bénard, senior research director at BC Cancer and radiology professor at the University of B.C. 'We can image this entire area of the body in one shot, so you can do things that we could not do before.' In a nutshell, the new scanners give better quality images in less time and requires less radioactive drugs than previous machines, he told CTV News. A PET/CT scanner combines two imaging devices, positron emission technology, which looks at biochemistry, and computed tomography, which provides anatomical information. A PET scan requires an injection of a radioactive substance called a tracer, while a conventional CT scan does not. B.C. is home to three PET/CT machines, in Vancouver, Victoria and Kelowna. Notably, the new Quadra machine is the fastest of its kind, which means more scans can be performed and patients get a more comfortable experience. Bénard says it can take more time to position a patient in the machine than take the picture itself. 'When I started my career, it would take two hours to take a PET scan, now we can get a better PET/CT scan in less than 30 seconds,' he said. Bénard added that those getting a PET scan on an older machine need not worry—they are also very precise. 'If you're not getting a PET scan on that machine you should be reassured. BC Cancer has very modern instruments at other sites,' he said. What this new scanner will do right away is add capacity for more diagnostics and provide research opportunities in the radiopharmaceutical field at UBC, according to Bénard. In May, the BC Cancer Centre in Vancouver also got a state-of-the-art photon-counting CT scanner. With files from CTV News Vancouver's Spencer Harwood
